Compare

MeiraGTx/$MGTX

1D1W1M3M6MYTD1Y5YMAX

About MeiraGTx

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
Ticker
$MGTX
Sector
Health
Primary listing
NASDAQ
Employees
386

MeiraGTx Metrics

BasicAdvanced
$780M
9.19
$0.87
1.07
-

What the Analysts think about MeiraGTx

Analyst ratings (Buy, Hold, Sell) for MeiraGTx stock.
Analyst projections of the future price of MeiraGTx stock.

Bulls say / Bears say

AAV2-hAQP1 showed symptom and saliva-flow improvements lasting three years in a 24-person Phase 1 study, and the FDA granted it Breakthrough Therapy designation. A positive pivotal read-out could support a filing. (MeiraGTx)
MeiraGTx reacquired bota-vec for $25 million and plans global regulatory filings in 2026; its manufacturing and quality-control facilities are commercially licensed. XLRP has no approved treatment, offering potential for a first-to-market therapy if regulators accept the evidence. (MeiraGTx)
The company secured up to $400 million from Oberland Capital, including an initial $125 million in royalty financing, and says its available resources should fund operations into the second half of 2028. That eases near-term funding pressure as it approaches key trial and filing milestones. (MeiraGTx)
Bota-vec failed to improve vision-guided mobility, the primary endpoint in its Phase 3 trial. MeiraGTx is pursuing filings despite that setback, leaving its approval prospects uncertain. (Fierce Biotech)
AAV2-hAQP1’s encouraging three-year results came from just 24 patients in an open-label Phase 1 study. Its pivotal Phase 2 read-out is not expected until the second quarter of 2027, so efficacy in a controlled trial remains unproven. (PubMed, MeiraGTx)
MeiraGTx reported $160.7 million of second-quarter net income, but also recognised $204.6 million of related-party licence revenue from granting Reogen rights to AAV-GAD and AAV-BDNF. That transaction-driven profit does not yet demonstrate a recurring earnings base from product sales. (MeiraGTx)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.

MeiraGTx Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

MeiraGTx Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.